Gefimipsa 250mg Capsule
Marketer
Ark Life Sciences Pvt Ltd
Salt Composition
Gefitinib (250mg)
Overview Gefimipsa 250mg Capsule
Efigraf 250mg capsules treat metastatic non-small cell lung cancer in patients with abnormal epidermal growth factor receptor (EGFR) genes and no prior cancer therapy. Dosage is determined by your physician and should be followed precisely throughout the prescribed course, which varies depending on individual response. Regular liver function monitoring may be advised. Common adverse reactions include nausea, diarrhea, dry skin, and appetite loss. Increased fluid intake may mitigate these effects. Report any persistent or worsening side effects, especially mouth sores, visual changes, or respiratory distress. Women should utilize effective contraception during treatment and for one month post-treatment to prevent pregnancy. Disclose all other medications to your doctor.
Primary Ingredients of Gefimipsa 250mg Capsule
No text provided to rephrase.
Uses of Gefimipsa 250mg Capsule
Lung cancer (excluding small cell type)
Major Benefits of Gefimipsa 250mg Capsule:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Gefimipsa 250mg Capsules can be administered with or without food, although consistent timing is recommended.
Common Side effects of Gefimipsa 250mg Capsule:
- Diarrhea
- Dry skin
- Loss of appetite
- Nausea
- Rash
- Vomiting
- Weakness
- Weight loss
- Eating disorder
- Allergic reaction
How to use Gefimipsa 250mg Capsule:
Follow your doctor's instructions precisely regarding dosage and treatment length for Gefimipsa 250mg Capsules. These capsules can be ingested with or without food, however, consistency in administration time is recommended.
How Gefimipsa 250mg Capsule works:
Oncaspar 250mg capsules are a cancer treatment. Their mechanism of action involves inhibiting the activity of a faulty protein responsible for triggering cancer cell proliferation. This effect contributes to the retardation or cessation of cancer progression.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol alongside Gefimipsa 250mg Capsules is inadvisable.
PregnancyCONSULT YOUR DOCTOR
Using Gefimipsa 250mg capsules during pregnancy poses a confirmed risk to the fetus. Therefore, its use is inadvisable. Nevertheless, a physician might exceptionally prescribe it in life-threatening circumstances where the potential advantages outweigh the known hazards. Always seek medical counsel.
Breast feedingCONSULT YOUR DOCTOR
The use of 250mg Gefimipsa capsules while breastfeeding is likely inadvisable. Available human data indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.
DrivingUNSAFE
Driving ability may be impaired by the side effects of Gefimipsa 250mg capsules.
KidneyCAUTION
Patients with severe kidney impairment should use Gefimipsa 250mg capsules cautiously. Dosage modification of Gefimipsa 250mg capsules may be necessary. Physician consultation is advised.
LiverSAFE IF PRESCRIBED
The use of 250mg Gefimipsa capsules in patients with liver disease appears to pose minimal risk. Existing evidence indicates dose modification may be unnecessary, but physician consultation is recommended.
What if you forget to take Gefimipsa 250mg Capsule :
Omit any missed Gefimipsa 250mg Capsule and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Gefimipsa 250mg Capsule
| Label | Value |
|---|---|
| Type of Compound | Quinazoline-based amines |
| Potential for Dependence | None. |
| Type of Treatment | Cancer-fighting drugs |
3,018 People bought this recently